Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENS-501 gene therapy for OTOF-related severe to profound hearing loss in young children
2023-504466-28-00Phase 2Authorised
- Sponsor
- Sensorion
- Start
- Jan 2024
- Modality
- Engineered AAV → AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of SENS-501 in sensorineural hearing loss (SNHL) and congenital hearing loss, sponsored by Sensorion. Primary endpoints: Safety in Part 1 and Efficacy (ABR improvement) in Part 2. Planned start Jan 2024; status: authorised.
02
Drugs
SENS-501
03
Conditions
sensorineural hearing loss (SNHL)congenital hearing loss
Beyond the preview
Go deeper on 2023-504466-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504466-28-00.